Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01444898 · ClinicalTrials.gov registry record · NA
Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
A NA study of Prader-Willi Syndrome, sponsored by Children's Hospital Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01444898: Completed NA study of Prader-Willi Syndrome, sponsored by Children's Hospital Los Angeles.
NCT01444898 is a NA study of Prader-Willi Syndrome that has completed, run by Children's Hospital Los Angeles. The registered enrollment target is 10 participants, below the 70-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01444898, a NA study of Prader-Willi Syndrome, has completed, sponsored by Children's Hospital Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Prader-Willi Syndrome (PWS) is one of the most common genetic causes of obesity. Obesity is a major source of morbidity and mortality in this population. It can lead to sleep apnea, cor pulmonale, diabetes mellitus, and atherosclerosis. PWS has distinct characteristics that set it apart from other forms of obesity including insatiable appetite and food-seeking behavior which can be disruptive to home and school activities, and can cause severe social and psychological turmoil within families. PWS is also associated with unique hormonal abnormalities, most notably hyperghrelinemia. Ghrelin is a gut hormone produced in the stomach that stimulates food intake during a fast. It is hypothesized that the extremely high ghrelin levels in patients with PWS may cause or contribute to their insatiable appetite. Exenatide, a medication used in the treatment of type 2 diabetes mellitus in adults, appears to suppress ghrelin levels and cause weight loss. It was designed to mimic glucagon-like peptide 1 (GLP-1), an incretin hormone that stimulates insulin secretion and delays gastric emptying, among other effects. In the present study, the investigators will investigate the effects of a 6 month trial of exenatide in overweight adolescents with PWS. The investigators will quantify the changes in weight and body composition, as well as subjective measures of appetite, and concentrations of appetite-associated hormones. The investigators hypothesize that exenatide will improve weight, body composition, appetite, and plasma ghrelin levels during the treatment period.
Primary Outcome
Change in weight (kg) after 6 months of treatment with study drug. Described as mean +/- SD
Conditions Studied
Interventions
- DRUG Exenatide
Study Locations (1)
California
- Children's Hospital of Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-12 |
| Phase | NA |
What the finished NCT01444898 record still lists
NCT01444898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 70-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Prader-Willi Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Exenatide is the first listed.
NCT01444898 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01444898 about?
NCT01444898 is a clinical study titled "Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome". Prader-Willi Syndrome (PWS) is one of the most common genetic causes of obesity. Obesity is a major source of morbidity and mortality in this population. It can lead to sleep apnea, cor pulmonale, diabetes mellitus, and atherosclerosis. PWS has distinct characteristics that set it apart from other f...
What is the current status of trial NCT01444898?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2012-03. Estimated completion is 2013-12.
What conditions does trial NCT01444898 study?
This clinical trial studies the following conditions: Prader-Willi Syndrome.
What interventions are being tested in trial NCT01444898?
The interventions under investigation include: Exenatide (DRUG).
Who is sponsoring clinical trial NCT01444898?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01444898 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prader-Willi Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01444898's enrollment target sits among peer trials
10 17th of 16 the lowest of 16 other Prader-Willi Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prader-Willi Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Cerebellar TMS and Satiety in Prader-Willi Syndrome
RECRUITING · NA
-
Impact of Bright Light Therapy on Prader-Willi Syndrome
RECRUITING · NA
-
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
RECRUITING · Phase 3
-
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
RECRUITING · Phase 1
-
A Study of Pitolisant in Patients With Prader-Willi Syndrome
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia